Live Breaking News & Updates on Amit Gaggar

Stay updated with breaking news from Amit gaggar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

UAB spinoff to treat chronic respiratory disease announces $3 million seed funding


Credit: UAB
BIRMINGHAM, Ala. - A biomedical research company founded by a University of Alabama at Birmingham physician-scientist has received $3 million in seed funding.
ResBiotic Inc. spun off from UAB last year will use the money to develop and commercialize groundbreaking probiotic formulations for lung health, says founder C. Vivek Lal, M.D., an associate professor in the UAB Department of Pediatrics, Division of Neonatology. The seed round was funded from a private equity syndicate led by Birmingham-based investment firm Timberline Holdings.
ResBiotic s first product aims to supplement the nutritional needs in chronic lung diseases. The product was developed in Lal s Pulmonary Microbiome Lab at UAB, with research and expertise from UAB s Microbiome Center, Lung Health Center, and the Translational Research in Normal & Disordered Development program. ....

Namasivayam Ambalavanan , Andrew Oconnor , C Vivek Lal , Jon Nugent , Braxton Goodrich , Scott Bush , Amit Gaggar , Sanjay Singh , Microbiome Center , Resbiotic Inc , Division Of Neonatology , Lal Pulmonary Microbiome Lab , Innovation For The Birmingham Business Alliance , Resbiotech Innovation Institute , University Of Alabama At Birmingham , Timberline Holdings , Department Of Cell , Division Of Pulmonary , Translational Research In Normal Disordered Development , Department Of Pediatrics , Department Of Medicine , Lung Health Center , Pulmonary Microbiome Lab , Translational Research , Disordered Development , Innovation Depot ,

ResBiotic Raises $3M in Seed Funding


Resbiotic, Inc., a Bilmingham, Ala.-based biotech startup, raised $3M in seed funding.
The round was funded from a private equity syndicate led by Timberline Holdings. Braxton Goodrich (Timberline Holdings) will serve on the ResBiotic Board of Directors.
The company intends to use the funds for the development and commercialization of probiotic formulations for lung health.
ResBiotic is the flagship company of ResBiotech Innovation Institute, founded by physician scientist Dr. C Vivek Lal in 2020. ResBiotic’s first product, a medical food that targets the gut-lung axis, was developed in Dr. Lal’s Pulmonary Microbiome Lab at UAB with research and expertise from the university’s Microbiome Center, Lung Health Center and Translational Research in Normal & Disordered Development (TReNDD) program. The proprietary probiotic blend has been shown to reduce neutrophilic inflammation in individuals with chronic respiratory conditions. The company’s research and ....

Vivek Lal , Namasivayam Ambalavanan , Andrew Oconnor , Scott Bush , Amit Gaggar , Braxton Goodrich , Sanjay Singh , Microbiome Center , Resbiotic Inc , Lal Pulmonary Microbiome Lab , Resbiotech Innovation Institute , Timberline Holdings , Translational Research In Normal Disordered Development Tre , Harvard University , Lung Health Center , Resbiotic Board , Pulmonary Microbiome Lab , Translational Research , Disordered Development , Executive Vice President , Casey Morrow , James Mike Wells , Scientific Advisory , Critical Care Medicine , Chief Medical , Andrewo Connor ,

ResBiotic, Inc. Raises $3M Seed Round and Announces Leadership Team


Share this article
Share this article
BIRMINGHAM, Ala., April 29, 2021 /PRNewswire/ University of Alabama at Birmingham s biotech startup Resbiotic, Inc. today announced a $3M seed round to support the development and commercialization of groundbreaking probiotic formulations for lung health. The round was funded from a private equity syndicate led by Timberline Holdings.  
ResBiotic is the flagship company of ResBiotech Innovation Institute, founded by physician scientist Dr. C Vivek Lal in 2020. ResBiotic s first product, a medical food that targets the gut-lung axis, was developed in Dr. Lal s Pulmonary Microbiome Lab at UAB with research and expertise from the university s Microbiome Center, Lung Health Center and Translational Research in Normal & Disordered Development (TReNDD) program. The proprietary probiotic blend has been shown to reduce neutrophilic inflammation in individuals with chronic respiratory conditions. The company s research and developmen ....

United States , University Of Alabama At Birmingham , Namasivayam Ambalavanan , Andrew Oconnor , Scott Bush , Amit Gaggar , C Vivek Lal , Jon Nugent , Sanjay Singh , Prnewswire University , Microbiome Center , Resbiotic Inc , Innovation For The Birmingham Business Alliance , Lal Pulmonary Microbiome Lab , Resbiotech Innovation Institute , Timberline Holdings , Braxton Goodrich Timberline Holdings , Translational Research In Normal Disordered Development Tre , Harvard University , Lung Health Center , Pulmonary Microbiome Lab , Translational Research , Disordered Development , Chief Scientific Officer , Braxton Goodrich , Resbiotic Board ,